LTR Pharma (ASX:LTP) agreed to collaborate with Strategic Drug Solutions to co-develop Oroflow, a novel intranasal spray targeting esophageal motility disorders, according to a Thursday filing with the Australian bourse.
Esophageal motility disorders are conditions that disrupt the normal movement of food and liquids down the esophagus, leading to swallowing difficulties and impacting quality of life, the filing said.
The program is set to begin proof-of-concept testing in the coming months, according to the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。